Evaluation of pharmacokinetics (PK) and safety of the Medtronic endeavor drug (ABT-578) [zotarolimus] eluting coronary stent system in de novo native coronary artery lesions.

Trial Profile

Evaluation of pharmacokinetics (PK) and safety of the Medtronic endeavor drug (ABT-578) [zotarolimus] eluting coronary stent system in de novo native coronary artery lesions.

Completed
Phase of Trial: Phase II/III

Latest Information Update: 04 Nov 2015

At a glance

  • Drugs Zotarolimus (Primary)
  • Indications Angina pectoris; Coronary artery disease; Myocardial infarction
  • Focus Pharmacokinetics
  • Acronyms ENDEAVOR-PK
  • Sponsors Medtronic
  • Most Recent Events

    • 19 Apr 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 22 Jun 2011 Planned end date changed from 1 Apr 2011 to 1 Aug 2011 as reported by ClinicalTrials.gov.
    • 15 Mar 2010 Five-year pooled analysis of ENDEAVOR programme including 3-year results from this trial presented at the 59th Annual Scientific Session of the American College of Cardiology (ACC), according to a Medtronic media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top